{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-22-000002","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2022-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.699718+00:00","generated_at":"2026-06-27T13:37:14.278260+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Keros Therapeutics appoints Christopher Rovaldi as COO effective Feb 1, 2022","bullets":["Christopher Rovaldi appointed Chief Operating Officer, effective February 1, 2022.","Rovaldi brings 20+ years experience, most recently as consultant and president of NS Biopharma Consulting.","Previously held senior roles at Acceleron Pharma (2007-2018), including SVP Program Management and Operations.","Initial annual base salary of $470,000; target bonus 50% of salary; option to purchase 100,000 shares.","Severance includes 9-12 months base salary and COBRA, with equity acceleration upon change of control termination."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-22-000002","json":"https://secwatch.observer/filing/0001664710-22-000002.json","markdown":"https://secwatch.observer/filing/0001664710-22-000002.md","text":"https://secwatch.observer/filing/0001664710-22-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471022000002/0001664710-22-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471022000002/kros-20220128.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T13:37:14.278260+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d7b20d0019","claim":"Christopher Rovaldi was appointed as Chief Operating Officer at Keros Therapeutics, Inc..","evidence_excerpt":"Christopher Rovaldi has been appointed to serve as the Company’s Chief Operating Officer, effective as of February 1, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1664710/000166471022000002/0001664710-22-000002-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}